Volume 46, Issue 7 , Pages 831-839, July 2007
Adherence to Pharmacological Treatment for Juvenile Bipolar Disorder
To access this article, please choose from the options below
The Stanley Medical Research Institute primarily supported this study. It was also supported in part by an NIMH Developing Centers for Interventions and Services Research Grant ( P20 MH-66054 ), NIHT32 HD041923-05 , NIHT32 HD041923-05 . Medications for the clinical trial were provided in part by Abbott Laboratories. The work of Susan Wood in processing this manuscript is gratefully acknowledged.Disclosure: Dr. Calabrese has received pharmaceutical income, research grant support, honoraria, and compensation for consultation from Abbott, AstraZeneca, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson Pharmaceutical Research & Development, Solvay/Wyeth, Bristol-Myers Squibb, and Eli Lilly. Dr. Findling receives or has received research support from, acted as a consultant to, and/or served on the speakers' bureaus of Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka, Pfizer, Sanofi-Aventis, Shire, Solvay, and Wyeth. The other authors have no financial relationships to disclose.
PII: S0890-8567(09)62171-7
doi:10.1097/chi.0b013e31805c7421
© 2007 The American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Volume 46, Issue 7 , Pages 831-839, July 2007
